Cingulate Announces Phase 3 CTx-1301 ADHD Data Published In Journal Of Child And Adolescent Psychopharmacology, With Placebo-Adjusted Effect Sizes Of 0.737 To 1.185

Loading news article.

Cingulate Announces Phase 3 CTx-1301 ADHD Data Published In Journal Of Child And Adolescent Psychopharmacology, With Placebo-Adjusted Effect Sizes Of 0.737 To 1.185 | WAPE

Cingulate Announces Phase 3 CTx-1301 ADHD Data Published In Journal Of Child And Adolescent Psychopharmacology, With Placebo-Adjusted Effect Sizes Of 0.737 To 1.185

Article summary

Related companies

Comments —